

# Drei Jahre Corona Pandemie

-


## Wo stehen wir?

Carsten Watzl

# Confirmed COVID-19 cases, deaths, hospital admissions, and patients in ICU per million people

Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.

**LINEAR** LOG  Align axis scales



Hospital admissions (per 1M)

No matching data

Patients in ICU (per 1M)

No matching data

New deaths (per 1M)

No matching data

Source: Johns Hopkins University CSSE COVID-19 Data, Official data collated by Our World in Data

F Feb 29, 2020

Feb 1, 2020

CC BY

Nov 27, 2022


# Confirmed COVID-19 cases, deaths, hospital admissions, and patients in ICU per million people

Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.


**LINEAR** LOG  Align axis scales

Germany


### New cases (per 1M)




### Hospital admissions (per 1M)



### Patients in ICU (per 1M)



### New deaths (per 1M)



Source: Johns Hopkins University CSSE COVID-19 Data, Official data collated by Our World in Data

Feb 1, 2020

Feb 17, 2021

Feb 1, 2020




Nov 27, 2022

Impfen

# Confirmed COVID-19 cases, deaths, hospital admissions, and patients in ICU per million people





Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.

**LINEAR** LOG  Align axis scales




Stand: 23.08.2022 (Impfungen)  
Quelle: impfdashboard.de, RKI, BMG.

Germany



Source: John Snow Labs, University of Toronto, CSSE COVID-19 Data, Official data collat Data


# Impfungen



Aus: Abbas, Cellular and Molecular Immunology, 8th edition

## Immungedächtnis

# Impfungen



Aus: Abbas, Cellular and Molecular Immunology, 8th edition

## Immungedächtnis

# Confirmed COVID-19 cases, deaths, hospital admissions, and patients in ICU per million people

Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.


**LINEAR** LOG  Align axis scales

Germany


### New cases (per 1M)




### Hospital admissions (per 1M)



### Patients in ICU (per 1M)



### New deaths (per 1M)



Source: Johns Hopkins University CSSE COVID-19 Data, Official data collated by Our World in Data

Feb 1, 2020

Jul 7, 2021

CC BY


Feb 1, 2020




Nov 27, 2022



# 2-Phasiger Abfall der Antikörper




# Impfungen




Aus: Abbas, Cellular and Molecular Immunology, 8th edition

## Immungedächtnis


# Antikörper nach Impfung oder Infektion




# Antikörper nach Impfung oder Infektion



# Antikörper nach Impfung oder Infektion



# Antikörper nach Impfung oder Infektion




# Die $\delta$ Welle

## Confirmed COVID-19 cases, deaths, hospital admissions, and patients in ICU per million people

Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.


**LINEAR** LOG  Align axis scales

Verimpfte Dosen Grundimmunisierungen Auffrischungsimpfungen  
Zweite Auffrischungsimpfungen




Stand: 23.08.2022 (Impfungen)  
Quelle: impfdashboard.de, RKI, BMG.


### New cases (per 1M)




### Hospital admissions (per 1M)



### Patients in ICU (per 1M)



### New deaths (per 1M)



Source: John Snow Labs, University of Oxford, CSSE COVID-19 Data, Official data collated by Our World in Data

Feb 1, 2020

Dec 29, 2021

CC BY

|| Feb 1, 2020  Sep 30, 2022

Impflücke



# Confirmed COVID-19 cases, deaths, hospital admissions, and patients in ICU per million people

Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.

**LINEAR** LOG  Align axis scales

Germany


### New cases (per 1M)




### Hospital admissions (per 1M)



### Patients in ICU (per 1M)



### New deaths (per 1M)




Source: Johns Hopkins University CSSE COVID-19 Data, Official data collated by Our World in Data



CC BY

Feb 1, 2020 Dec 30, 2021 Jan 26, 2023

# Das Virus verändert sich



\* inkl. Sublinien



**Immunitätslücke?**

# Wie hoch ist die Immunität in Deutschland?

	N (Teilnehmer*innen)	N (Kohorten)	S-AK, krude			NC-AK, krude		
			Anteil	95% LCI	95% UCI	Anteil	95% LCI	95% UCI
	6301	6	98,9%	97,9%	99,4%	43,2%	35,9%	50,7%
<b>Alter (Jahre)</b>								
12-17	76	6	97,8%	96,0%	98,8%	62,6%	52,4%	71,9%
18-29	205		99,6%	97,0%	100,0%	53,8%	41,8%	65,4%
30-34	295		99,4%	98,5%	99,7%	47,2%	43,3%	51,2%
35-39	270		99,0%	94,1%	99,8%	57,2%	46,5%	67,3%
40-49	733		98,5%	97,2%	99,2%	54,3%	46,5%	61,9%
50-59	1617		98,8%	97,9%	99,3%	42,8%	35,4%	50,5%
60-64	845		99,1%	97,5%	99,7%	38,9%	31,0%	47,5%
65-79	1905		99,2%	98,5%	99,6%	31,3%	27,3%	35,6%
>80	169		99,5%	97,9%	99,9%	26,6%	17,5%	38,2%


Jäger et al., Interimsanalyse des IMMUNEBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an die Modellierungskonsortien der BMBF-geförderten Modellierungsplattformen  
<https://doi.org/10.5281/zenodo.6968574>

# Wie hoch ist die Immunität in Deutschland?

	N (Teilnehmer*innen)	N (Kohorten)	S-AK, krude			NC-AK, krude		
			Anteil	95% LCI	95% UCI	Anteil	95% LCI	95% UCI
	6301	6	98,9%	97,9%	99,4%	43,2%	35,9%	50,7%
<b>Alter (Jahre)</b>								
12-17	76	6	97,8%	96,0%	98,8%	62,6%	52,4%	71,9%
18-29	205		99,6%	97,0%	100,0%	53,8%	41,8%	65,4%
30-34	295		99,4%	98,5%	99,7%	47,2%	43,3%	51,2%
35-39	270		99,0%	94,1%	99,8%	57,2%	46,5%	67,3%
40-49	733		98,5%	97,2%	99,2%	54,3%	46,5%	61,9%
50-59	1617		98,8%	97,9%	99,3%	42,8%	35,4%	50,5%
60-64	845		99,1%	97,5%	99,7%	38,9%	31,0%	47,5%
65-79	1905		99,2%	98,5%	99,6%	31,3%	27,3%	35,6%
>80	169		99,5%	97,9%	99,9%	26,6%	17,5%	38,2%

Jäger et al., Interimsanalyse des IMMUNEBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an die Modellierungskonsortien der BMBF-geförderten Modellierungsplattformen  
<https://doi.org/10.5281/zenodo.6968574>

# Wie hoch ist die Immunität in Deutschland?



Jäger et al., Interimsanalyse des IMMUNEBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an die Modellierungskonsortien der BMBF-geförderten Modellierungsplattformen  
<https://doi.org/10.5281/zenodo.6968574>

# Confirmed COVID-19 cases, deaths, hospital admissions, and patients in ICU per million people

Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.


**LINEAR** LOG  Align axis scales

Germany


### New cases (per 1M)




### Hospital admissions (per 1M)



### Patients in ICU (per 1M)



### New deaths (per 1M)




Source: Johns Hopkins University CSSE COVID-19 Data, Official data collated by Our World in Data

CC BY



Source: Johns Hopkins University CSSE COVID-19 Data, Official data collated by Our World in Data. <https://ourworldindata.org>

# Aktuelle Lage in Deutschland



BA.2 - 21%

BA.5 - 37%

Sublinien:

BQ.1.1. - 14%

XBB.1.5 - 27%

Abbildung 23: Prozentuale Anteile der einzelnen SARS-CoV-2 Sublinien mit einem Anteil >1 % in der aktuellen Berichtswoche, bezogen auf die Genomsequenzen aus der Stichprobe, absteigend sortiert nach ihrem Anteil in KW 7/2023. Sublinien von BA.5 sind in Blautönen, Sublinien von BA.2 in Rottönen und Rekombinanten in Brauntönen dargestellt. Die Reihenfolge der Sublinien in der Legende entspricht der Abfolge von oben nach unten in der Abbildung.



# Ausblick




Abb. 1: Vergleich der für die Bevölkerung in Deutschland geschätzten ARE-Raten (in Prozent) in den Saisons 2017/18 bis 2022/23 (bis zur 8. KW 2023). Der senkrechte Strich markiert den Jahreswechsel.

# Ausblick




Abb. 4: Anteil der Nachweise für Influenzaviren, hCoV, SARS-CoV-2, RSV, hMPV, PIV und Rhinoviren (Positivenraten; rechte y-Achse) an allen im Rahmen des Sentinels eingesandten Proben (linke y-Achse, graue Balken) von der 40. KW 2022 bis zur 8. KW 2023.

# Ausblick



# Ausblick



LongCOVID

Vulnerable Gruppen

**VIELEN DANK FÜR IHRE AUFMERKSAMKEIT UND  
BLEIBEN SIE GESUND!**